Aviance Capital Partners LLC Sells 2,266 Shares of Pfizer Inc. (NYSE:PFE)

Aviance Capital Partners LLC lessened its position in Pfizer Inc. (NYSE:PFE) by 3.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 66,488 shares of the biopharmaceutical company’s stock after selling 2,266 shares during the period. Aviance Capital Partners LLC’s holdings in Pfizer were worth $1,914,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Briaud Financial Planning Inc bought a new stake in shares of Pfizer in the 3rd quarter worth approximately $30,000. Mizuho Securities Co. Ltd. bought a new stake in Pfizer in the third quarter valued at $34,000. VisionPoint Advisory Group LLC raised its holdings in Pfizer by 52,350.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 1,047 shares in the last quarter. GoalVest Advisory LLC lifted its position in shares of Pfizer by 304.9% in the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 811 shares during the period. Finally, Tennessee Valley Asset Management Partners bought a new stake in shares of Pfizer during the 4th quarter valued at about $36,000. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Up 1.3 %

Shares of Pfizer stock traded up $0.36 on Monday, reaching $28.17. The company’s stock had a trading volume of 59,821,979 shares, compared to its average volume of 43,254,852. The company has a market capitalization of $159.51 billion, a price-to-earnings ratio of -469.50, a P/E/G ratio of 1.17 and a beta of 0.63. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $40.37. The firm’s fifty day simple moving average is $26.90 and its two-hundred day simple moving average is $28.14.

Pfizer (NYSE:PFE) last issued its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. The business had revenue of $14.88 billion during the quarter, compared to analyst estimates of $13.87 billion. Pfizer had a positive return on equity of 8.58% and a negative net margin of 0.56%. Pfizer’s revenue was down 19.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.23 EPS. Equities analysts anticipate that Pfizer Inc. will post 2.39 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be given a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 5.96%. The ex-dividend date is Thursday, May 9th. Pfizer’s dividend payout ratio (DPR) is presently -2,800.00%.

Analysts Set New Price Targets

PFE has been the subject of several research analyst reports. Morgan Stanley raised their price objective on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a report on Thursday. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Monday, April 15th. Guggenheim started coverage on Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective for the company. BMO Capital Markets reiterated an “outperform” rating and issued a $36.00 price target (up from $33.00) on shares of Pfizer in a research note on Thursday. Finally, Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Eleven analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, Pfizer presently has a consensus rating of “Hold” and an average price target of $36.00.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.